|
|
|
|
||
CAR-T''Gilead expects to file an IND for an allogeneic anti-CD19 CAR-T therapy (KITE-037) during 2H19 BCMA CAR-T program discontinued ZUMA-2: Filing for FDA approval of KTE-X19 in MCL in 2H19 ZUMA-3: Completing enrollment in a pivotal phase 2 of KTE-X19 in adult ALL in 2Q19. ZUMA-5: A pivotal phase 2 trial of YESCARTA in r/r indolent NHL, enrollment completed in 1Q19 ZUMA-6: A phase 2 trial in combination with a PD-L1 inhibitor, initiated in 1Q18 ZUMA-7: A pivotal phase 3 trial in second-line DLBCL'' |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
11845 | Re: CAR-T | spaddy | 0 | 2/7/2019 8:59:30 PM |